Tesamorelin + Ipamorelin Blend
A GH-axis pairing built on tesamorelin, the only GHRH analog with a full FDA approval, run alongside the cleanly selective GHRP ipamorelin.
This blend combines two growth-hormone-axis peptides in a single vial: tesamorelin, a 44-amino-acid GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy, and ipamorelin, a selective ghrelin-receptor (GHS-R1a) pentapeptide. Pairing a GHRH leg with a GHRP leg activates two separate pituitary receptors at once, producing a larger, synergistic growth-hormone pulse than either arm alone. The receptor-pair pharmacology is well established and the individual components are strongly documented, but the combined product has no fixed-dose outcome trial and tesamorelin's approval does not cover this blend or this use.
Class
GHRH analog (44-aa) + selective GHRP pentapeptide blend
Half-life
Tesamorelin ~26-38 minutes (subQ); ipamorelin ~2 hours
Routes
Subcutaneous injection
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Synergistic growth-hormone release
Tesamorelin drives the GHRH receptor and ipamorelin drives the ghrelin receptor on the same pituitary somatotrophs, amplifying pulse amplitude more than either arm alone. This dual-receptor synergy is established human pharmacology, demonstrated by Bowers in 1990 in normal men.
Selective visceral-fat reduction (tesamorelin arm)
Pooled phase 3 data in HIV-associated lipodystrophy (n=806) showed a 15-18% CT-measured reduction in visceral adipose tissue at 26 weeks with subcutaneous fat unchanged. This trial-grade record is the strongest data point on the pairing, though it derives from the HIV population rather than the blend.
Clean GHRP signaling (ipamorelin arm)
Ipamorelin supplies the ghrelin-receptor arm with the cleanest selectivity in its class. Raun 1998 established no measurable change in cortisol, prolactin, FSH, LH, TSH, or ACTH even at 200x the effective GH-release dose, which is why it is the preferred GHRP.
Downstream IGF-1 and body composition
The released growth hormone drives liver IGF-1, the downstream signal behind body-composition and recovery effects. Tesamorelin's label notes IGF-1 roughly doubles on therapy.
Sleep and recovery (reported)
Users and clinics report improved sleep depth, recovery, and modest body-composition shifts over weeks to months. These are uncontrolled observations on an off-label use rather than measured blend outcomes, but they are pharmacologically plausible through GH-axis signaling.
Mechanism
How it works
The blend hits both arms of growth-hormone release at once. Tesamorelin, a 44-amino-acid GHRH analog, supplies the GHRH-receptor signal that tells pituitary somatotrophs to fire. Ipamorelin, a selective ghrelin-receptor (GHS-R1a) pentapeptide, supplies the ghrelin-receptor signal on those same cells. Because the two peptides act on separate receptors, together they amplify GH pulse amplitude more than either arm produces alone.
This GHRH-plus-GHRP synergy is textbook receptor-pair pharmacology and was demonstrated in humans by Bowers in 1990, who showed the two arms release GH synergistically in normal men. It is the same dual-receptor logic that built the more common CJC-1295 + ipamorelin stack, extended here by swapping in the GHRH leg with the strongest human record.
The growth hormone released by the pulse drives hepatic IGF-1 production, the downstream signal behind the pairing's body-composition and recovery effects. Tesamorelin's selective effect on visceral adipose tissue is phase 3 documented in HIV-associated lipodystrophy, while ipamorelin's contribution is a clean GH pulse that does not move cortisol, prolactin, or ACTH at clinically relevant doses.
What the pharmacology does not include is a fixed-blend outcome trial. Nobody has run tesa+ipa as a combined product with defined endpoints, so the evidence is component-derived plus clinical practice pattern. Tesamorelin's FDA approval covers HIV-associated visceral fat, meaning the strongest data point sits one step removed from what is actually in the vial.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Practice pattern (not standardized)
- Dose
- Not standardized; vial ratios and formulations vary by source
- Frequency
- Not specified in source
- Timing
- Not specified in source
- Duration
- Weeks to months per user/clinic reports
- Route
- Subcutaneous injection
There is no FDA-approved dosing framework for the blend. Tesamorelin alone has a labeled dose for HIV-associated lipodystrophy; the combined product does not. Community route and schedule claims are practice patterns, not label instructions.
- No fixed-dose tesa+ipa product is FDA-approved and no blend dosing framework exists; the source does not report specific mcg/mg regimens for the combination.
- Tesamorelin's label (for its HIV indication) notes glucose-tolerance changes and roughly doubled IGF-1, both monitored in its trials.
- Reconstitution and vial ratios vary by source; the source file does not specify a reconstitution protocol for the blend.
Evidence
Research & clinical studies (3)
Growth hormone (GH) release synergism between GHRH and a GH-releasing peptide in normal men
Bowers demonstrated that the GHRH and GHRP arms release growth hormone synergistically in normal men, establishing the dual-receptor pharmacology behind GHRH+GHRP pairings.
Tesamorelin pooled phase 3 program in HIV-associated lipodystrophy
Pooled phase 3 data (n=806) showed a 15-18% CT-measured reduction in visceral adipose tissue at 26 weeks, with subcutaneous fat unchanged, supporting tesamorelin's FDA approval as Egrifta.
Ipamorelin, the first selective growth hormone secretagogue
Raun established ipamorelin's selectivity, showing no measurable change in cortisol, prolactin, FSH, LH, TSH, or ACTH even at 200x the effective GH-releasing dose.
Combinations
Stacking & blends
Tesa + Ipa (the blend itself)
Synergistic pulsatile GH release combining a trial-grade GHRH leg with a clean GHRP leg
Tesamorelin activates the GHRH receptor and ipamorelin activates the ghrelin receptor on the same somatotrophs, producing a larger GH pulse than either alone while ipamorelin adds no cortisol or prolactin spike.
CJC-1295 + Ipamorelin
The more common GHRH+GHRP stack for GH-axis support
The source frames CJC+ipa as the more common GHRH-plus-GHRP stack that the tesa+ipa pairing extends by swapping in the GHRH leg with the most human data.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Prohibited in competitive sport (both compounds on WADA prohibited list)
Reported effects track the individual components. Tesamorelin's label notes glucose-tolerance changes and roughly doubled IGF-1, both monitored in its trials. These observations are largely uncontrolled and drawn from an off-label use rather than a blend outcome trial.
FAQ
Tesamorelin + Ipamorelin Blend — common questions
What is the tesamorelin / ipamorelin blend?
A combination of two growth-hormone-axis peptides in a single vial: tesamorelin, a GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy, and ipamorelin, a selective ghrelin-receptor agonist. Together they hit both arms of GH release for synergistic pulsatile stimulation.
What does tesamorelin / ipamorelin do?
It stimulates pulsatile growth-hormone release through two complementary receptors. Tesamorelin (GHRH) tells pituitary somatotrophs to fire; ipamorelin (GHRP) amplifies the pulse via the ghrelin receptor. Sleep, recovery, and body-composition claims for the pairing are mostly clinic and community reports layered on component pharmacology, not direct blend trial outcomes.
How is tesamorelin / ipamorelin typically administered?
Research and clinic formulations vary, and there is no FDA-approved dosing framework for the blend. Tesamorelin alone has a labeled dose for HIV-associated lipodystrophy; the combined product does not. Community route and schedule claims are practice patterns, not label instructions.
What are the side effects of tesamorelin / ipamorelin?
Reported effects track the individual components: injection-site reactions, transient flushing, mild fluid retention, joint aches from GH/IGF-1 signaling, and occasional hunger from the ipamorelin half. Tesamorelin's label notes glucose-tolerance changes and roughly doubled IGF-1, both monitored in its trials.
Is tesamorelin / ipamorelin FDA approved?
The blend is not. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy, a narrow indication; using it in a GH-axis recomp blend is off-label. Ipamorelin has no FDA approval and lost the 503A compounding pathway after the October 2024 FDA PCAC vote. Both are on the WADA prohibited list.
Why pair tesamorelin instead of CJC-1295 or sermorelin?
Tesamorelin is the GHRH analog with the strongest human record: pooled phase 3 in HIV-associated lipodystrophy (n=806) showed 15-18% CT-measured visceral-fat reduction at 26 weeks, and it carries a full FDA approval as Egrifta. The pairing reaches for that trial-grade GHRH leg plus ipamorelin's clean GHRP leg.
Does the blend actually work?
Yes on receptor logic, with an honest asterisk on the product. The GHRH-plus-GHRP synergy is established in humans, tesamorelin's visceral-fat effect is phase 3 documented, and ipamorelin's selectivity is well characterized. The missing piece is a fixed-blend outcome trial: no one has run tesa+ipa as a combined product with endpoints.
